ARTICLE | Clinical News
GlycoMimetics reports Phase II data for sickle cell therapy
April 17, 2013 12:11 AM UTC
GlycoMimetics Inc. (Gaithersburg, Md.) reported top-line data on Tuesday from a Phase II trial evaluating twice-daily IV GMI-1070 to treat vaso-occlusive crisis in 76 hospitalized patients with sickle cell disease. GMI-1070 reduced duration of vaso-occlusive crisis, length of hospital stay and use of narcotic pain relief compared to placebo. GlycoMimetics said the trial was not powered to detect statistical significance and declined to disclose details. ...